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Abstract 
 
How the dialysis dose is normalized is just one of several assumptions that clinicians need to 
take into account when prescribing peritoneal dialysis. El-Kateb et al. confirm that 
estimating the volume of urea distribution is associated with significant error and show that 
energy expenditure is not linearly related to volume, such that there is a potential need for 
a higher dialysis prescription in smaller, more active individuals. Although this should be 
born in mind, this is not the patient group that causes the greatest clinical concern, at least 
in the short term.  
Rightly or wrongly, peritoneal dialysis guidelines have adopted the urea kinetic modelling 
approach, (Kt/V), originally developed for haemodialysis, to measure and set standards for 
adequacy of treatment.1 There are many potential flaws in this approach, including the 
emphasis on small solute clearance and the fact that the largest study investigating the 
benefits of increasing peritoneal dialysis dose and thus informing practice, the ADEMEX 
trial, actually used creatinine clearance as its intervention target.2 However here we will 
focus on the issue of how the dose should be normalized to account for patient specific 
attributes – usually size. The current approach is simple: urea is assumed to be distributed 
uniformly in the body water, so to determine clearance its removal is divided by the volume 
of distribution. More of a problem is the estimate of this volume, which has up to a 25% 
error when using the Watson formula,3 especially in obese or malnourished patients, a 
concern to which we will return. 
 
There are many, however, that question validity of the urea kinetic model, arguing that 
dialysis should be scaled not to volume of distribution but measures of metabolic activity, 
either by using a metric that is more closely aligned to this – for example body surface area 
(BSA) or an estimate of metabolic rate and energy expenditure. One of the arguments for 
this is the observation of differential effects of increasing the dialysis dose by gender in the 
HEMO study, the suggestion being that the relative benefit for women reflected a need for 
more dialysis due to their relatively higher metabolic rate for a given volume of distribution, 
4, see figure.5 It’s worth pointing out that this effect of gender was not seen in the ADEMEX 
study;2 this might be because the creatinine clearance target was normalized to BSA, but 
could equally reflect the very different kinetics of urea removal by these dialysis modalities. 
 
For the first time, in this issue of Kidney International, El-Kateb et al. have sought to 
understand the impact of normalising the dialysis dose to estimated total energy 
expenditure rather than volume of distribution.6 To do this they employed a validated 
questionnaire to determine total and resting energy expenditure that was developed from 
double isotopic labelled water experiments. They compared the differential effect of 
normalising by first determining the theoretical (not measured) value for Kt, assuming a 
Kt/V of 1.7 for all patients (the minimum advised target) by substituting the estimates of V 
made by either the Watson formula or bioimpedance analysis, and then dividing this value 
of Kt by the total or resting energy expenditure. In this way they were able to show that 
individuals who are smaller, especially women, more active or employed would receive less 
clearance per unit of energy expenditure. 
 
Although of definite interest, interpreting the meaning of these results if fraught with 
complexity. First, it is important to be clear whether smaller size is a consequence of 
otherwise healthy gender/size differences or due to being under-nourished. Although the 
authors did not include formal measures of dietary protein intake, they did measure 
comorbidity, frailty and inflammation. Broadly speaking the predictions made by this study 
indicate that this is a gender/size issue rather than an issue of malnutrition, and thus largely 
explained by scaling, again see figure.5 For example, the effect of different approaches to 
normalising the Kt were not worse in patients with lower protein catabolic rate or more 
frailty – if anything the opposite was seen. Care has to be taken, however, as it is known 
that protein nitrogen appearance underestimates dietary protein intake in PD patients as 
the comorbidity increases leading to under-recognition of malnutrition.7 This is one of the 
flaws in urea kinetic modelling, which assumes steady state, whereas in fact sicker patients 
are likely to be in negative nitrogen balance. Second, maintaining stable nitrogen balance, 
which is surely one of the main goals of adequate dialysis dosing which the urea kinetic 
model is aiming to facilitate, is complex in PD patients. When PD was first introduced there 
was considerable concern that a higher protein intake would be required to compensate for 
peritoneal protein losses. This has not turned out to be the case however, and detailed 
nitrogen balance studies have shown that this can be maintained in prevalent patients 
provided there is sufficient total calorie intake – a significant proportion of which being 
derived from absorption of dialysate glucose.8 The suggestion from El-Kateb’s study that 
more active, employed PD patients might be at risk from under-dialysis is perhaps best 
rectified by simply ensuring they have adequate calorie intake rather than increasing the 
dialysis dose. Third, the majority of these patients, >85%, had significant residual kidney 
function and we know from previous studies that residual versus peritoneal Kt/V brings very 
different benefits which cannot be accounted for in the methodology used in this study.9 If 
the actual, rather than theoretical Kt as determined here was disproportionately derived 
from residual kidney function in the more active and employed patients, as was likely to 
have been the case, then increasing their dialysis dose would not necessarily be required. 
Indeed, given the cross sectional nature of the study it is impossible to determine the 
direction of cause and effect. It would have been more informative if the study had been 
undertaken in patients actually receiving a Kt/V of 1.7, preferably anuric, but this is not a 
practical proposition and likely would have excluded many of the more active, employed 
patients. 
 
So how does this study affect clinical practice? Given the many problems associated with 
normalising the dialysis dose (and this study also confirms the problem of error in 
estimating volume, showing big differences, ±15%, in the use of the Watson formula versus 
bioimpedance for some patients) the use of a Kt/V can only be used as a rough guide, 
possibly a minimum standard, in patient management. The clinician needs to interpret the 
result with extreme care, perhaps substituting the ideal weight in the calculation for those 
at the extremes of size, cross referencing to the creatinine clearance normalized to BSA (so 
addressing the scaling concern) and working very closely with the dietician to establish if 
either protein or calorie intake is adequate. Should we be especially worried about women 
being under-dialysed? No studies have ever shown that survival of women on PD is worse 
than men, although there is some evidence that elderly diabetic women do less well on PD 
than HD, the explanations for which are far from clear. Active, working patients may 
struggle when anuric, so titrating the dialysis dose upwards may be worth considering while 
they are waiting for a successful transplant. 
 
  
References: 
 
1. Lo WK, Bargman JM, Burkart J et al. Guideline on targets for solute and fluid removal in 
adult patients on chronic peritoneal dialysis. Perit. Dial. Int. 2006; 26: 520–522. 
2. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on 
mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J. 
Am. Soc. Nephrol. 2002; 13: 1307–20. 
3. Chertow GM, Lazarus JM, Lew NL et al. Development of a population-specific regression 
equation to estimate total body water in hemodialysis patients. Kidney Int. 1997; 51: 1578–
82. 
4. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in 
maintenance hemodialysis. N. Engl. J. Med. 2002; 347: 2010–9. 
5. West GB. The importance of quantitative systemic thinking in medicine. Lancet 2012; 379: 
1551–1559. 
6. El-Kateb S, Sridharan S, Farrington K et al. A single weekly Kt/Vurea target for peritoneal 
dialysis patients does not provide an equal dialysis dose for all. Kidney Int 2016. 
7. Davies SJ, Russell L, Bryan J et al. Comorbidity, urea kinetics, and appetite in continuous 
ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. 
Am. J. kidney Dis. 1995; 26: 353–361. 
8. Bergström J, Fürst P, Alvestrand A et al. Protein and energy intake, nitrogen balance and 
nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Kidney 
Int. 1993; 44: 1048–57. 
9. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and 
peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J. Am. Soc. 
Nephrol. 2001; 12: 2158–62. 
 
  
Caption for Figure: 
Allometry is the study of biological scaling;5 allometric data can be expressed as linear 
functions log Y = log a + b log X, where b (the gradient), indicates the type of scaling 
relationship. Two well established examples are shown here, the surface area to volume 
relationship, m2/m3, where b=0.67 (green dashed line) and Kleiber’s law, which relates 
metabolic rate to mass across species, where b=0.75 is the typically quoted value (solid red 
line). In both cases the prediction is that smaller bodies will require more energy for a given 
weight upon which the argument rests that smaller people may need relatively more solute 
clearance. 
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